<DOC>
	<DOCNO>NCT02874742</DOCNO>
	<brief_summary>The purpose study determine addition daratumumab lenalidomide-bortezomib-dexamethasone ( RVd ) increase proportion subject achieve stringent complete response ( sCR ) , define International Myeloma Working Group ( IMWG ) criterion , time completion post autologous stem cell transplantation ( ASCT ) consolidation treatment , compare RVd alone .</brief_summary>
	<brief_title>Study Comparing Daratumumab , Lenalidomide , Bortezomib , Dexamethasone ( D-RVd ) Versus Lenalidomide , Bortezomib , Dexamethasone ( RVd ) Subjects With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Considered investigator eligible highdose chemotherapy ( HDT ) autologous stem cell transplantation ( ASCT ) accord institution 's criterion base age , medical history , cardiac pulmonary status , overall health condition , comorbid condition ( ) , physical examination , laboratory study Has prior systemic therapy multiple myeloma . An emergency course steroid ( define great 40 milligram [ mg ] dexamethasone , equivalent per day maximum 4 day ( , total 160 mg ) permit . In addition , radiation therapy permit prior study entry , screening , Cycles 12 study treatment need lytic bone disease Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Woman childbearing potential must 2 negative highly sensitive serum ( betahuman chorionic gonadotropin [ bhCG ] ) screening , first one within 10 14 day prior first dose component study treatment second within 24 hour prior first dose component study treatment A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction study ( include dose interruption ) , 4 week follow discontinuation lenalidomide , receive daratumumab , 3 month last dose Diagnosed treated malignancy multiple myeloma , except : ) Malignancy treat curative intent know active disease present equal ( &gt; = ) 3 year randomization ; b ) Adequately treat nonmelanoma skin cancer lentigo maligna without evidence disease ; c ) Adequately treat carcinoma situ ( example , cervical , breast ) evidence disease Exhibiting clinical sign know history meningeal central nervous system involvement multiple myeloma Known chronic obstructive pulmonary disease force expiratory volume 1 second ( FEV1 ) less ( &lt; ) 50 percent ( % ) predict normal Known moderate severe persistent asthma within past 2 year currently uncontrolled asthma classification Known seropositive human immunodeficiency virus , know hepatitis B surface antigen positivity , know history hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>